Print this page Close this page

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1590105

Dengue - Pipeline Review, Q1 2011

Description:
Dengue - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Dengue - Pipeline Review, Q1 2011', provides an overview of the Dengue therapeutic pipeline. This report provides information on the therapeutic development for Dengue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dengue. 'Dengue - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dengue.
- A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dengue pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dengue.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dengue pipeline depth and focus of Dengue therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Contents:


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dengue Overview
Therapeutics Development
An Overview of Pipeline Products for Dengue
Dengue Therapeutics under Development by Companies
Dengue Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Dengue Therapeutics - Products under Development by Companies
Dengue Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Dengue Therapeutics Development
United Therapeutics Corporation
Sanofi-Aventis
GlaxoSmithKline plc
Merck & Co., Inc.
Biotron Limited
Alfacell Corporation
AVI BioPharma Inc.
NanoViricides, Inc.
SIGA Technologies, Inc.
Phynova Group Ltd
MacroGenics, Inc.
Canopus BioPharma Incorporated
GenPhar, Inc.
Inviragen, Inc.
Dengue - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Dengue vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CYD Dengue Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
20% Diethyltoluamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue Therapeutics - Discontinued Products
Dengue - Featured News
Nov 04, 2010: Sanofi Pasteur’s Dengue Vaccine Enters First Phase III Clinical Study
Oct 25, 2010: Inviragen Initiates DENVax Phase I Clinical Testing In Colombia
May 19, 2010: Inviragen’s Dengue Vaccine to Begin Clinical Testing
Feb 17, 2010: NanoViricides Signs Research And Development Agreement With Dr. Eva Harris’s Laboratory At UC Berkeley For Dengue Program
Aug 25, 2009: Hawaii Biotech Initiates Phase 1 Clinical Trial For Dengue Vaccine
Apr 21, 2009: Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded To Singapore And Vietnam
Apr 21, 2009: Sanofi Pasteur Presents Positive Results Of Tetravalent Dengue Candidate Vaccine
Feb 18, 2009: Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
Sep 12, 2008: NIH Funds SIGA Dengue Antiviral Program
May 21, 2008: SIGA Advances Dengue Antiviral Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Dengue, Q1 2011
Products under Development for Dengue – Comparative Analysis, Q1 2011
Comparative Analysis by Late Stage Development, Q1 2011
Comparative Analysis by Mid Clinical Stage Development, Q1 2011
Comparative Analysis by Early Clinical Stage Development, Q1 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q1 2011
United Therapeutics Corporation, 2011
Sanofi-Aventis, 2011
GlaxoSmithKline plc, 2011
Merck & Co., Inc., 2011
Biotron Limited, 2011
Alfacell Corporation, 2011
AVI BioPharma Inc., 2011
NanoViricides, Inc., 2011
SIGA Technologies, Inc., 2011
Phynova Group Ltd, 2011
MacroGenics, Inc., 2011
Canopus BioPharma Incorporated, 2011
GenPhar, Inc., 2011
Inviragen, Inc., 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Discontinued Products

List of Figures
Number of Products under Development for Dengue, Q1 2011
Products under Development for Dengue – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Late Stage Products, Q1 2011
Mid Clinical Stage Products, Q1 2011
Early Clinical Stage Products, Q1 2011
Discovery and Pre-Clinical Stage Products, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011
Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed Friday, May 24, 2013
10:12:53 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Dengue - Pipeline Review, Q1 2011

Web Address

http://www.researchandmarkets.com/reports/1590105

Office Code

OC8DIQSNPPPWXR

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EURO€ 384.00
Electronic (PDF) - Site License EURO€ 769.00
Electronic (PDF) - Enterprisewide EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Friday, May 24, 2013
10:12:53 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)